



25 August 2022

Dear Healthcare Professional,

Re: Temporary shortage of LUCRIN (leuporelin acetate) Depot 3-month 11.25mg prefilled dual chamber syringe (PDS)

AbbVie Limited anticipates a temporary shortage of LUCRIN Depot 3-month 11.25mg PDS (Pharmacode 2330156) until approximately 23rd September 2022. The temporary shortage is due to the supply of product and is not related to the product quality. AbbVie is working to resolve this situation with the utmost urgency.

During this period, continuity of LUCRIN therapy may be maintained by using the alternative LUCRIN Depot 1-month 3.75mg PDS presentation.¹ There is no shortage of the LUCRIN Depot 1-month 3.75mg PDS, and both the LUCRIN Depot 1-month 3.75mg PDS and LUCRIN Depot 3-month 11.25mg PDS presentations are approved for the treatment of prostate cancer, uterine fibroids, endometriosis and breast cancer (in which hormone therapy is specified).¹

Please note that the LUCRIN Depot 1-month 3.75mg PDS is formulated to be administered with a dosing frequency of once per month.¹ When using LUCRIN Depot 1-month 3.75mg PDS as an alternative option, do not concurrently administer a combination of doses due to different release characteristics as LUCRIN Depot 1-month 3.75 mg PDS is formulated to deliver the dose over the course of a month rather than over the course of 3 months. The bioavailability of this alternative option is comparable when administered at the recommended dosing frequency.¹ Before prescribing please refer to the current approved LUCRIN Data Sheet for further information available at www.medsafe.govt.nz.

LUCRIN Depot 1-month 3.75mg PDS and LUCRIN Depot 3-month 11.25mg PDS are part-funded by Pharmac for most patients. LUCRIN is fully funded for children and adolescents who are unable to tolerate administration of goserelin. If a patient is paying a part-charge for LUCRIN treatment, there may be a variation in the cost to the patient if the clinical decision is made to prescribe the alternative LUCRIN Depot 1-month 3.75mg PDS dose.

We apologise for any inconvenience to you and your patients. We will notify you once the LUCRIN Depot 3-Month 11.25mg PDS shortage is resolved. For further information regarding the alternative LUCRIN dose option please contact AbbVie Medical Information on 0800 900 030 or by email at medinfoanz@abbvie.com. Please note that Pharmac has updated its website to include information about this supply issue. Pharmac will update this webpage as further information becomes available.

Yours sincerely,

Alan Watts PhD
Medical Director Australia & New Zealand

References:

1. Lucrin Depot 3.75mg and 11.25mg Prefilled Dual-Chamber Syringe (PDS) Injection Approved Data Sheet. V10 Dated 11 January 2022.

NZ-LUCR-220001